VTVT
vTv Therapeutics Inc.
Healthcare — Biotechnology
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.
Price History
Fundamentals
| Market Cap | $138.09M |
| P/E Ratio (TTM) | - |
| Forward P/E | -9.01 |
| EPS (TTM) | $-0.78 |
| Dividend Yield | - |
| Profit Margin | 6.11% |
| Revenue Growth | - |
| ROE | -1.47% |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | $53.00 |
| Analysts | 6 |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 60.2 |
| Beta | 0.27 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $44.00 |
| 52-Week Low | $14.00 |
| 50-Day Avg | $33.75 |
| 200-Day Avg | $32.19 |
| Avg Volume | 53.1K |
| Volume | 2.4K |
Performance Analysis
NEUTRALVTVT presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:37 UTC
Back to Screener Export Report